Compare · CBOE vs CHNA
CBOE vs CHNA
Side-by-side comparison of Cboe Global Markets, Inc. (CBOE) and Loncar China BioPharma ETF (CHNA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CBOE and CHNA operate in n/a (n/a), so they compete in similar markets.
- CBOE carries a market cap of $13.01B.
- CBOE has hit the wire 2 times in the past 4 weeks while CHNA has been quiet.
- CBOE has more recent analyst coverage (25 ratings vs 0 for CHNA).
Cboe Global Markets, Inc.
Cboe Global Markets, Inc., through its subsidiaries, operates as an options exchange worldwide. It operates through five segments: Options, North American Equities, Futures, European Equities, and Global FX. The Options segment trades in listed market indices. The North American Equities segment trades in listed U.S. and Canadian equities; and offers exchange-traded products (ETP) transaction and ETP listing services. The Futures segment trades in futures. The European Equities segment offers pan-European listed equities transaction services, ETPs, exchange-traded commodities, and international depository receipts, as well as ETP listings and clearing services. The Global FX segment provides institutional foreign exchange (FX) trading and non-deliverable forward FX transactions services. The company has strategic relationships with S&P Dow Jones Indices, LLC; FTSE International Limited; Frank Russell Company; MSCI Inc.; and DJI Opco, LLC. The company was formerly known as CBOE Holdings, Inc. and changed its name to Cboe Global Markets, Inc. in October 2017. Cboe Global Markets, Inc. was founded in 1973 and is headquartered in Chicago, Illinois.
Loncar China BioPharma ETF
The investment seeks to track the performance, before fees and expenses, of the Loncar China BioPharma Index (the index). Under normal circumstances, at least 80% of the fund's total assets (exclusive of any collateral held from securities lending) will be invested in the component securities of the index or in depositary receipts representing such component securities. The index seeks to track the performance of a modified equal-weighted portfolio of companies directly involved in the growth of China's pharmaceutical and biotech related industries. The fund is non-diversified.
Latest CBOE
- Cboe Global Markets Announces Date of Second-Quarter 2026 Earnings Release and Conference Call
- Cboe Global Markets Reports Trading Volume for June 2026
- Director Tomczyk Fredric J covered exercise/tax liability with 337 shares, decreasing direct ownership by 0.94% to 35,631 units (SEC Form 4) (withholding tax)
- Cboe Global Markets, Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
- Cboe Introduces Cboe Predicts, Launching First Products in New Prediction Markets Suite
- Cboe Global Markets downgraded by Erste Group
- Cboe Global Markets Reports Trading Volume for May 2026
- SEC Form 3 filed by new insider Fischer Heidi
- Cboe Receives SEC Approval to Offer Extended Trading Hours for Select Multi-Listed Single Stock Options
- Cboe Hires Boudewijn Duinstra as Executive Vice President, Chief Risk Officer
Latest CHNA
No recent items for Loncar China BioPharma ETF.